CoChat

Clinical review on triglycerides

Open access

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index; 38 of the 145 sources its claims cite were checked for support.

Abstract

Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.

Overview

CoChat Summary

TL;DR

This clinical review summarizes that triglyceride-rich lipoproteins and their remnants contribute to atherosclerotic cardiovascular disease, while severe hypertriglyceridaemia raises pancreatitis risk. It discusses lifestyle, established fibrates/omega-3/niacin, and emerging therapies including apo C-III and ANGPTL3 inhibitors.

Key findings

  • Hypertriglyceridaemia is common, with prevalence ∼10% in adults; severe HTG (TG >10 mmol/L) has prevalence 0.10–0.20%, and very severe HTG (TG >20 mmol/L) 0.014%. Genetic and epidemiologic data establish TRL/remnants as ASCVD contributors; rare heterozygous APOC3 loss-of-function variants are associated with ∼50% reduced TG levels and reduced ASCVD risk.
  • HTG is believed causative in 1–10% of acute pancreatitis episodes. Pancreatitis risk is elevated (HR 2.4) at TG 2.0–3.0 mmol/L but absolute risk remains low (5.5 events per 10 000 patient-years); acute pancreatitis may occur in 3% of those with TG 10–20 mmol/L and 15% of those with TG >20 mmol/L, while a German cohort reported 19% with TG >1000 mg/dL.
  • Fibrates can reduce TG by up to 70%; statins, ezetimibe, and PCSK9 inhibitors reduce TG by 5–15%; high-dose omega-3 fatty acids (>2 g/day) variably decrease TG. In REDUCE-IT, 4 g icosapent ethyl in >9000 high-risk patients produced an ASCVD hazard ratio of 0.75 over 4.9 years.
  • Volanesorsen reduced TG by 77% vs an 18% increase with placebo in APPROACH, and by 72% vs 1% increase in COMPASS. Emerging agents include pemafibrate (35–45% TG reduction), evinacumab (TG and LDL-C reductions up to 75% and 23%), IONIS-ANGPTL3-LRx (TG and LDL-C reductions up to 63.1% and 32.9%), and pradigastat (70% fasting TG reduction in six FCS patients).

Methods

  • Narrative clinical review; no primary data collection. It synthesizes epidemiologic, genetic, mechanistic, and randomized trial evidence and includes tables on primary/secondary causes, lifestyle effect sizes, randomized cardiovascular outcome trials, acute pancreatitis treatment, and emerging therapies.
  • Main analysis is qualitative synthesis; no systematic search strategy, inclusion criteria, or formal risk-of-bias assessment is described.

Limitations

  • Stated: randomized controlled trial evidence for specific dietary recommendations is lacking; there is a lack of convincing outcomes evidence for ASCVD reduction when fibrates, omega-3 fatty acids, or niacin are added to statin therapy; no high-quality trial data demonstrate that acute pancreatitis risk decreases with specific TG-lowering therapy; efficacy and safety of emerging treatments need assessment in outcome trials.
  • Evident: as a narrative review, it does not report a systematic literature search or formal quality appraisal, and conclusions rely on selected studies and ongoing trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz785

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1 Overview of triglyceride-rich lipoprotein metabolism focused on disease genes and drug targets. Triglyceride-rich lipoprotein assembly begins with triglyceride synthesis, which derive from fatty acids in the intestine from the diet or in the liver taken up from plasma, fatty acids released from lysosomes after breakdown of endocytosed triglyceride-rich lipoproteins, and fatty acids generated from glucose by de novo lipogenesis. A series of enzymes, culminating in tissue-specific isoforms of diacylglycerol acyltransferase in intestine and liver, produce triglyceride. Microsomal triglyceride transfer protein unites triglyceride, cholesterol, and phospholipids, with tissue-specific isoforms of apolipoprotein (apo) B, i.e. small B-48, shortened as a result of RNA editing in enterocytes and full-length B-100 in hepatocytes, forming chylomicrons and very-low-density lipoprotein, respectively. Chylomicrons formation also requires Sar1 homolog B GTPase (SAR1B gene product, not shown). Chylomicrons enter plasma indirectly through lymphatics while very-low-density lipoprotein is secreted directly into the circulation. Hydrolysis of circulating chylomicrons and very-low-density lipoprotein by lipoprotein lipase releases free fatty acids and produce chylomicron remnant clearance and intermediate-density lipoprotein particles, respectively. Chylomicrons remnant clearance by the liver (not shown) requires apo E, as apo B-48 does not have the low-density lipoprotein receptor binding domain. Intermediate-density lipoprotein can also be removed by the liver (not shown) with apo B-100 and apo E both acting as ligands for the low-density lipoprotein receptor. Intermediate-density lipoprotein can be further lipolyzed by lipoprotein lipase and also remodelled by hepatic lipase to generate low-density lipoprotein, which is cleared by the low-density lipoprotein receptor, whose activity is reduced by proprotein convertase subtilisin kexin 9. The inset depicts lipoprotein lipase activity on a triglyceride-rich lipoprotein particle as well as several interacting proteins at the endothelial surface that affect lipoprotein lipase activity. A plus sign indicates enhancement or stimulation of lipolysis, whereas a minus sign indicates inhibition. Lipase maturation factor 1 (LMF1) is a chaperone protein that ensures that lipoprotein lipase attains functionality and is properly secreted from adipose cells or myocytes. Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein-1 (GPIHBP1) is necessary for transcytosis of lipoprotein lipase across the endothelium of capillaries in adipose and muscle tissues as well as tethering lipoprotein lipase to the endothelium, thereby stabilizing it. Apo C-II activates lipoprotein lipase, while apo A-V is a stabilizing cofactor. Lipolysis is reduced by apo C-III, which is a component of triglyceride-rich lipoproteins, and by angiopoietin-like proteins 3 and 4 (ANGPTL3 and ANGPTL4), which both operate near the endothelium. Volanesorsen and AKCEA-APOCIII-LRx reduce triglyceride by targeting apo C-III, while evinacumab and IONIS-ANGPTL3-LRx lower triglyceride by targeting ANGPTL3. Peroxisome proliferator-activated receptors (not shown), particularly alpha and delta types, form a regulatory network that influences several of the above target molecules. Adapted from Ref.13
Figure 1 Overview of triglyceride-rich lipoprotein metabolism focused on disease genes and drug targets. Triglyceride-rich lipoprotein assembly begins with triglyceride synthesis, which derive from fatty acids in the intestine from the diet or in the liver taken up from plasma, fatty acids released from lysosomes after breakdown of endocytosed triglyceride-rich lipoproteins, and fatty acids generated from glucose by de novo lipogenesis. A series of enzymes, culminating in tissue-specific isoforms of diacylglycerol acyltransferase in intestine and liver, produce triglyceride. Microsomal triglyceride transfer protein unites triglyceride, cholesterol, and phospholipids, with tissue-specific isoforms of apolipoprotein (apo) B, i.e. small B-48, shortened as a result of RNA editing in enterocytes and full-length B-100 in hepatocytes, forming chylomicrons and very-low-density lipoprotein, respectively. Chylomicrons formation also requires Sar1 homolog B GTPase (SAR1B gene product, not shown). Chylomicrons enter plasma indirectly through lymphatics while very-low-density lipoprotein is secreted directly into the circulation. Hydrolysis of circulating chylomicrons and very-low-density lipoprotein by lipoprotein lipase releases free fatty acids and produce chylomicron remnant clearance and intermediate-density lipoprotein particles, respectively. Chylomicrons remnant clearance by the liver (not shown) requires apo E, as apo B-48 does not have the low-density lipoprotein receptor binding domain. Intermediate-density lipoprotein can also be removed by the liver (not shown) with apo B-100 and apo E both acting as ligands for the low-density lipoprotein receptor. Intermediate-density lipoprotein can be further lipolyzed by lipoprotein lipase and also remodelled by hepatic lipase to generate low-density lipoprotein, which is cleared by the low-density lipoprotein receptor, whose activity is reduced by proprotein convertase subtilisin kexin 9. The inset depicts lipoprotein lipase activity on a triglyceride-rich lipoprotein particle as well as several interacting proteins at the endothelial surface that affect lipoprotein lipase activity. A plus sign indicates enhancement or stimulation of lipolysis, whereas a minus sign indicates inhibition. Lipase maturation factor 1 (LMF1) is a chaperone protein that ensures that lipoprotein lipase attains functionality and is properly secreted from adipose cells or myocytes. Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein-1 (GPIHBP1) is necessary for transcytosis of lipoprotein lipase across the endothelium of capillaries in adipose and muscle tissues as well as tethering lipoprotein lipase to the endothelium, thereby stabilizing it. Apo C-II activates lipoprotein lipase, while apo A-V is a stabilizing cofactor. Lipolysis is reduced by apo C-III, which is a component of triglyceride-rich lipoproteins, and by angiopoietin-like proteins 3 and 4 (ANGPTL3 and ANGPTL4), which both operate near the endothelium. Volanesorsen and AKCEA-APOCIII-LRx reduce triglyceride by targeting apo C-III, while evinacumab and IONIS-ANGPTL3-LRx lower triglyceride by targeting ANGPTL3. Peroxisome proliferator-activated receptors (not shown), particularly alpha and delta types, form a regulatory network that influences several of the above target molecules. Adapted from Ref.13CC BY-NC · PubMed Central

Verification

Claims the paper makes

19 Valid · 13 Not valid · 76 Not checked · 34 Own results and interpretations

75 more claims · 9 with their cited sources checked

Create a free account to see all 142 claims and to verify the 107 references still open.

See all claims — free account
  • It may state two separate claims as one. 52
  • Probably not a substantial claim. 15
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 101 references

Cited by

See all 573

Metadata

Authors
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A.
Affiliations
  • University Hospital Leipzig (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • Columbia University (US)
  • Western University (CA)
Corresponding author
Laufs, Ulrich
Venue
European Heart Journal
Published
2019-11-25
Volume
41
Issue
1
Pages
99-109c
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2991262768
Cited by
544
References
101
Citations by year
2026: 62 · 2025: 81 · 2024: 99 · 2023: 90 · 2022: 84 · 2021: 74 · 2020: 50 · 2019: 3
FWCI
10.88
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
hypertriglyceridemia, triglyceride-rich lipoproteins, atherosclerotic cardiovascular disease, pancreatitis, non-HDL cholesterol, apolipoprotein B, LDL cholesterol, fibrates, omega-3 fatty acids, lipid-lowering therapy, diet and lifestyle, new drugs
MeSH terms
Humans, Life Style, Triglycerides, Hypertriglyceridemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical review on triglycerides. https://app.cochat.ai/papers/10.1093/eurheartj/ehz785
The paper
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020). Clinical review on triglycerides. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.